More than 100 Cuban and foreign researchers continues debating today in Havana on progresses and new actions of CIMAvax-EGF, first therapeutic vaccine registered for lung cancer.
The event, to be concluded today, was opened yesterday at the Havana’s Conference Center, an excellent opportunity to assess new strategies of the medicine, such as its implementation in medical practice, indications and therapeutic combinations.
Doctor Agustin Lage, director of the Center of Molecular Immunology, talked in the opening ceremony about the situation of cancer, and the use of therapeutic vaccines as part of the treatment of this disease.
He stated that globally, of all patients with malignant tumors, about three percent are receiving some form of immunotherapy, and the prediction is that in the coming decade this kind of therapy reaches 60 percent.
“The questions is not today whether immunotherapy is or not effective, but how long and in which patients,” the scientist noted.
In statements to Prensa Latina, Lage explained that Cimavax-EGF is making itself way worldwide. Several clinical trials are being ongoing in European and Latin American countries, and the interest for the product is growing, as that showed by U.S. scientists who recently visited the island.